Osama Saher

Osama Saher

Postdoctoral researcher

About me

A Post-doc researcher excited to establish useful connections between worlds of pharmaceutical sciences and molecular biology.

Research description

Research area/interest: Gene Therapy, Pharmaceutical Sciences, Drug Delivery.

Selected publications:

1. Saher O, Ghorab DM, Mursi NM. Preparation and in vitro / in vivo evaluation of antimicrobial ocular in situ gels containing a disappearing preservative for topical treatment of bacterial conjunctivitis. Pharm Dev Technol. 2016;21(5):600-610. doi:10.3109/10837450.2015.1035728

2. Saher O, Ghorab DM, Mursi NM. Levofloxacin hemihydrate ocular semi-sponges for topical treatment of bacterial conjunctivitis: Formulation and in-vitro/in-vivo characterization. J Drug Deliv Sci Technol. 2016;31(December 2015):22-34. doi:10.1016/j.jddst.2015.11.004

3. Saher O, Rocha CSJ, Zaghloul EM, et al. Novel peptide-dendrimer/lipid/oligonucleotide ternary complexes for efficient cellular uptake and improved splice-switching activity. Eur J Pharm Biopharm. 2018;132(August):29-40. doi:10.1016/j.ejpb.2018.09.002

4. Saher O, Lehto T, Gissberg O, et al. Sugar and Polymer Excipients Enhance Uptake and Splice-Switching Activity of Peptide-Dendrimer/Lipid/Oligonucleotide Formulations. Pharmaceutics. 2019;11(12):666. doi:10.3390/pharmaceutics11120666

5. Ezzat K, Pernemalm M, Pålsson S, et al. The viral protein corona directs viral pathogenesis and amyloid aggregation. Nat Commun. 2019;10(1):2331. doi:10.1038/s41467-019-10192-2

6. Hande M, Saher O, Lundin K, Smith C, Zain R, Lönnberg T. Oligonucleotide–Palladacycle Conjugates as Splice-Correcting Agents. Molecules. 2019;24(6):1180. doi:10.3390/molecules24061180

7. Gupta D, Liang X, Pavlova S, et al. Quantification of extracellular vesicles in vitro and in vivo using sensitive bioluminescence imaging. J Extracell Vesicles. 2020;9(1):1800222. doi:10.1080/20013078.2020.1800222

8. Estupiñán HY, Bouderlique T, He C, et al. Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects. Blood Adv. 2020;4(11):2439-2450. doi:10.1182/bloodadvances.2019001319

9. Bazaz S, Lehto T, Tops R, et al. Novel Orthogonally Hydrocarbon-Modified Cell-Penetrating Peptide Nanoparticles Mediate Efficient Delivery of Splice-Switching Antisense Oligonucleotides In Vitro and In Vivo. Biomedicines. 2021;9(8):1046. doi:10.3390/biomedicines9081046

10. Umek T, Olsson T, Gissberg O, et al. Oligonucleotides Targeting DNA Repeats Downregulate Huntingtin Gene Expression in Huntington’s Patient-Derived Neural Model System. Nucleic Acid Ther. 2021;31(6):443-456. doi:10.1089/nat.2021.0021

11. Daralnakhla H, Saher O, Zamolo S, et al. Lipophilic Peptide Dendrimers for Delivery of Splice-Switching Oligonucleotides. Pharmaceutics. 2021;13(1):116. doi:10.3390/pharmaceutics13010116

12. Bost JP, Ojansivu M, Munson MJ, et al. Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides. Commun Biol. 2022;5(1):185. doi:10.1038/s42003-022-03132-2

13. Bost JP, Saher O, Hagey D, et al. Growth Media Conditions Influence the Secretion Route and Release Levels of Engineered Extracellular Vesicles. Adv Healthc Mater. 2022;11(5):2101658. doi:10.1002/adhm.202101658